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Letter to the EditorEndogenous and exogenous sex
steroid hormones in asthma and
allergy in females: A systematic
review and meta-analysisTo the Editor:
Asthma and allergy are more common in males than in females
during early childhood, but the incidence, severity, and impact on
quality of life are greater in postpubertal females than in males.1,2
Female sex steroid hormones may partly explain these differ-
ences.1,2 In 2 previous systematic reviews, early menarche
(<12 years) was associated with an increased asthma risk,3
whereas no significant association was found betweenmenopause
and asthma, although subgroup analyses indicated an increased
risk in postmenopausal women using hormone replacement ther-
apy (HRT).4 Consideration of other hormonal factors, along with
the full spectrum of relevant outcomes, is necessary for a compre-
hensive appreciation of the underlying evidence base. We there-
fore undertook a systematic review investigating the role of
endogenous and exogenous hormonal factors in the development
and clinical expression of asthma and allergy in females.
Our methods were published a priori (PROSPERO:
2015:CRD42015026762).5 Further details are available in this ar-
ticle’s Online Repository at www.jacionline.org. We included
experimental and analytical epidemiological studies of females
from puberty to adulthood (<75 years). Exposures were puberty,
menarche, menstruation, menopause, hormonal contraceptives,
and HRT. Primary outcomes were self-reported or objectively
defined incidence or prevalence of asthma, asthma exacerbations,
asthma hospitalizations, and asthma medication use.
We searched 11 bibliographic databases, databases of ongoing
studies, and conference abstracts, and contacted experts for
articles published between January 1990 and November 2015
with no language restrictions. N.M. and B.I.N. independently
screened titles, abstracts, and full-text articles; extracted study
data; and assessed risk of bias using the Cochrane Risk of Bias
Tool (experimental studies) and the Effective Public Health
Practice Project tool (observational studies). Discrepancies
were resolved by discussion, or arbitration by A.S.
Adjusted effect estimates were combined in random-effects
meta-analyses, performed using Stata release 14 (StataCorp,
College Station, Tex). Meta-analyses were possible for studies on
menarche, menstruation, menopause, hormonal contraceptives,
and HRT. Stratified analyses were performed by body mass index
and smoking for HRT studies.
Of 22,488 articles retrieved, 64 (reporting 57 studies; obser-
vational: 51; experimental: 6) were included with 554,293
participants analyzed (see references E5 and E10-E72 and Fig
E1 in this article’s Online Repository at www.jacionline.org).
Study characteristics are available on request.
Detailed results are given in this article’s Online Repository at
www.jacionline.org; here, we present key findings. Compared
with typical menarche (11-13 years), early menarche 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).(<11 years) was associated with increased risk of new-onset
(odds ratio [OR], 1.49; 95% CI, 1.14-1.94) and ever asthma
(OR, 1.06; 95% CI, 1.03-1.10), whereas late menarche
(>13 years) was associated with increased risk of ever (OR,
1.11; 95% CI, 1.07-1.15), but not new-onset asthma (OR, 1.13;
95% CI, 0.82-1.56) (Fig 1).
Compared with regular menstruation, irregular menstruation
was associated with increased risk of current asthma (past
12 months) (OR, 1.59; 95% CI, 1.23-2.05) (see Fig E2, A, in
this article’s Online Repository at www.jacionline.org), specif-
ically for atopic (OR, 2.57; 95% CI, 1.66-3.98), but not nonatopic
asthma (OR, 0.95; 95% CI, 0.54-1.65) (Fig E2, B).
Compared with premenopause, menopause onset was associ-
ated with increased risk of current asthma (OR, 1.25; 95% CI,
1.04-1.51) and current wheeze (OR, 1.16; 95%CI, 1.05-1.30), but
not current allergic rhinitis (OR, 0.94; 95%CI, 0.81-1.10) (see Fig
E3 in this article’s Online Repository at www.jacionline.org).
Results for hormonal contraceptives were mixed, with both
increased and decreased risks reported (Fig E3).
Compared with never use, ever HRT use (hazard ratio [HR],
1.37; 95%CI, 1.22-1.54), past use (HR, 1.41; 95%CI, 1.22-1.63),
current use (HR, 1.48; 95% CI, 1.22-1.78), and current use of
estrogen-only HRT (HR, 1.85; 95% CI, 1.50-2.28) were associ-
ated with increased risk of new-onset asthma (Fig 2). Current use
was also associated with increased risk of current asthma (OR,
1.42; 95% CI, 1.18-1.70), and current wheeze (OR, 1.40; 95%
CI, 1.22-1.61), but not current allergic rhinitis (OR, 1.27; 95%
CI, 0.97-1.68) (Fig 2). The risk was higher in nonoverweight/non-
obese and nonsmoking women than in overweight/obese and
smoking women, respectively (see Fig E4 in this article’s Online
Repository at www.jacionline.org).
Forty-one of the 51 observational studies had moderate risk of
bias, whereas the rest had high risk; all 6 experimental studies had
high risk of bias (data available on request).
This is the most comprehensive synthesis to date linking sex
steroids to the development and expression of asthma and allergy in
females. We followed recommended steps for undertaking a high-
quality synthesis. However, the lack of high-quality experimental
studies limited assessment of causality and relevance to patient
care and policy. Although most epidemiological studies adjusted
for key confounders, this was often not comprehensive. Many
outcomes (eg, medication use, exacerbations, and hospitalizations)
were not assessed, and so there is little evidence in relation to these.
Questions that remain to be addressed center on the influence of
different types of sex steroids, dose and route of administration of
exogenous sex steroids, and the underlying biologic mechanisms
through which hormones may influence asthma and allergy. Early
menarche and irregular menstruation are often signs of anov-
ulation, indicating episodes of unopposed estrogen exposure to
target organs and absences of progesterone exposure.6 Estrogen-
only HRT was associated with asthma, whereas smoking, which
may influence estrogen metabolism,7 had a protective effect.
Although higher body mass index is generally associated with a
more estrogenic state8 and also an increased risk of asthma,9 we
found increased risk in both overweight/obese and nonover-
weight/nonobese HRT users. At the cellular level, estrogen can
have proinflammatory or anti-inflammatory effects, depending
on cell type and location. Explanations for the various1
FIG 1. Meta-analyses of studies that investigated associations between onset of menarche and asthma and
allergy in females. N.Europe, Northern Europe; RR, risk ratio. All effect estimates are adjusted. Weights are
from random-effects analysis. Early menarche: <11 years; late menarche: >13 years; the comparator group
in each analysis is typical menarche: 11 to 13 years.
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that all can be explained by one biological mechanism. Our re-
sults also suggest that atopy may be a contributing factor in
some instances (irregular menstruation) but not others (meno-
pause). The differences in findings for early and late menarche
may be due to the different asthma outcomes investigated: alter-
natively, the effect observed in cross-sectional studies may reflect
reverse causation. Further mechanistic work is required to eluci-
date any relationships, as are further longitudinal observational
studies with detailed phenotyping of participants.
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FIG 2. Meta-analyses of studies that investigated associations between the use of HRT and asthma and
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METHODS
Our methods are detailed in full in PROSPERO (2016: CRD42015026762)
and in our published protocol.E1
Eligibility criteria
Experimental studies (randomized controlled trials [RCTs], quasi-RCTs,
controlled-clinical trials [CCTs], controlled before-and-after studies, and
interrupted time series designs) and analytical epidemiological studies
(cohort, case-control, and cross-sectional studies) were eligible for inclusion.
Females from puberty to adulthood (<75 years) were eligible. There was no
fixed lower age limit of puberty; rather, we used the definitions given in each
article. Exposures were endogenous (ie, puberty, menarche, menstruation,
menopause) and exogenous (ie, hormonal contraceptives and HRT) hormonal
factors. Categories of exposures were defined according to the definitions used
in included studies (eg, early vs typical menarche, irregular vs regular
menstruation, pre- vs postmenopause, use vs nonuse of hormonal contracep-
tives, and duration of use of HRT). Our primary outcomes were self-reported
or objectively defined measures of incidence or prevalence of asthma, asthma
exacerbations, asthma hospitalizations, and use of asthma medications: again,
categories were defined according to the included studies (eg, has asthma
diagnosis or not, ever hospitalized for asthma). Our secondary outcomes were
wheeze, atopic dermatitis/eczema, allergic rhinitis, urticaria, angioedema,
food allergy, anaphylaxis, atopic sensitization, indicators of lung function, and
asthma-specific quality of life.
Search strategy and study selection
We searched 11 bibliographic databases (MEDLINE, EMBASE, Cochrane
Library, ISI Web of Science, CINAHL, Google Scholar, AMED, Global
Health, PsycINFO, CAB International, and WHO Global Health Library) for
articles published between January 1990 (because relevant studies were
published from the mid-1990s) and November 2015 with no language
restrictions. An example search strategy is provided in Appendix E1. Refer-
ences cited in included studies were screened, and international experts in
the field were contacted. Unpublished and ongoing studies were searched us-
ing ISI Conference Proceedings Citation Index via Web of Knowledge, ZE-
TOC (British Library), Current Controlled Trials, ClinicalTrials.gov, and the
Australian and New Zealand Clinical Trials Registry. Titles and abstracts of
retrieved articles and full-text copies of potentially relevant studies were
screened independently by 2 reviewers (N.M. and B.I.N.). Discrepancies
were resolved by discussion, or arbitration by a third reviewer (A.S.).
A record of reasons for rejection at the full-text screening stage was kept
and interreviewer agreement was assessed using the Kappa statistic.E2
Data extraction and risk-of-bias assessment
A data extraction form was developed, independently piloted by N.M. and
B.I.N., and refined before use. N.M. and B.I.N. independently extracted study
data and completed risk-of- bias assessments. Discrepancies were resolved by
discussion, or arbitration by A.S. The risk of bias in experimental studies was
assessed using the Cochrane Risk of Bias Tool.E3 For observational studies,
the Effective Public Health Practice Project tool was used (www.ephpp.ca/
tools.html). This tool was adapted for use, informed by the Research Triangle
Institute item bank.E4 Data extraction and risk-of-bias assessment were under-
taken by N.M. and U.N. for the study authored by B.I.N. and A.S.E5
Data analysis and reporting
Descriptive tables were produced to summarize the literature and character-
istics of studies contributing to the evidence. Effect estimates from studies
judged to be reasonably homogeneous in terms of their clinical, methodological,
and statistical aspects were combined in random-effectsmeta-analyses using the
inverse variance method.E6 Meta-analysis was possible only with observational
epidemiological studies and not with experimental studies, which were of low
quality and heterogeneous. The studies on puberty were heterogeneous; hence,
no meta-analysis was done; instead, we undertook a narrative synthesis of these
studies. Meta-analyses were performed for studies on menarche, menstruation,
menopause, hormonal contraceptives, and HRT. Studies eligible for meta-
analyses reported 1 of the following effect measures: HR, risk ratio, or OR.
We included only adjusted estimates in the meta-analyses. For studies of
HRT, stratified analyses were performed for body mass index (non vs over-
weight/obese) and smoking (nonvs ever-smoker). Heterogeneity was quantified
using the I2 statistic. To enhance comparability between studies that categorized
any of the exposures as binary, estimates fromexposure categories in studies that
used multiple exposure categories were collapsed using the Mantel-Haenszel
approachE7 before combining in meta-analyses. Evidence of publication bias
was assessed using Funnel plots and the Egger test.E8 All tests were 2-sided,
and P < .05 was considered statistically significant. Analyses were performed
using Stata release 14 (StataCorp). Reporting followed the recommendations
of the Preferred Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) checklist.E9
RESULTS
Study selection
A total of 22,488 records were retrieved, of which 64 articles
(reporting 57 studies) met the criteria to be included in the
review.E5,E10-E72 In total, 554,293 participants were analyzed
across the included studies. Of the 57 studies, 22 were included
in at least 1 meta-analysis. The 2 reviewers agreed on 99% of
the records at the title and abstract screening stage (k5 0.62 indi-
cating good or substantial agreement) and 88% at the full-text
article screening stage (k 5 0.76 indicating good or substantial
agreement).E2 Articles in non-English languages (ie, French,E67
Turkish,E10,E54 and RussianE11,E12) were translated. The literature
search and screening process are summarized in Fig E1.
Characteristics of included studies
Twenty-six studies exclusively investigated endogenous hor-
mones, 20 exclusively investigated exogenous hormones, and 11
investigated both. Of the 37 studies on endogenous hormones, 9
focused on puberty,E13,E24,E28,E33,E35,E53,E54,E56,E67,E70 22 on
menarche,E14,E21,E23-E25,E29-E31,E34,E37,E38,E43-E45,E48,E50,E53,E54,
E56,E57,E60,E62-E64,E71,E72 5 on menstruation,E22,E25,E30,E43-E45,E66
and 11 on menopause.E15,E17,E27,E32,E36,E39,E40,E42-E45,E62-
E64,E68,E69 Of the 31 studies on exogenous hormones, 17
focussed on hormonal contraceptives (15 observationa-
lE5,E23,E26,E29,E32,E37,E42,E47,E49,E50,E52,E60-E64,E69,E71 and 2
experimental studiesE46,E58) and 18 on HRT (14 obser-
vationalE11,E12,E16,E18,E19,E32,E36,E39-E42,E47,E51,E59,E63,E69 and 4
experimental studiesE10,E20,E55,E65). Asthma diagnosis was a
key outcome across studies, principally assessed on the basis
of self-reports or parent reports. Our other primary outcomes
were rarely assessed: 6 studies assessed asthma exacerbations,
asthma hospitalizations, or use of asthma medications. Second-
ary outcomes included self-reported atopic dermatitis/eczema,
wheeze, allergic rhinitis, and food allergy; measures of lung
function using spirometry; and specific/total IgE assessed using
serum samples. Detailed characteristics of included studies are
available on request.
Associations between endogenous sex hormones
and risk of asthma and allergy
Across studies, early onset of puberty was associated with an
increased risk of asthma, whereas late onset of puberty appeared
to be protective (data available on request). Age at menarche was
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grouped around the age of 11 to 13 years across most studies, with
early menarche typically defined as below this age and late
menarche as above. Compared with typical menarche (11-
13 years), early menarche was associated with increased risk of
new- onset asthma (OR, 1.49; 95%CI, 1.14-1.94) and ever asthma
(OR, 1.06; 95%CI, 1.03-1.10) (Fig 1), whereas latemenarchewas
associated with ever asthma (OR, 1.11; 95% CI, 1.07-1.15), but
not new-onset asthma (OR, 1.13; 95% CI, 0.82-1.56) (Fig 1).
Most menstruation studies focused on the impact of irregular
menstruation. Limited information regarding the definition of
irregular menstruation was provided in the studies included in
meta-analyses, with regularity of menstruation categorized on the
basis of self-reports of whether or not menstruation was regular,
or whether cycle length was greater than 32 days.E30,E44,E66
Compared with regular menstruation, irregular menstruation
was associated with increased risk of current asthma (having
had asthma in the past 12 months) (OR, 1.59; 95% CI, 1.23-
2.05), but not current wheeze (OR, 1.25; 95% CI, 0.92-1.71)
(Fig E2, A). Stratifying by atopic status, irregular menstruation
was associated with current atopic asthma (OR, 2.57; 95% CI,
1.66-3.98), but not with current nonatopic asthma (OR, 0.95;
95% CI, 0.54-1.65) (Fig E2, B).
Compared with the premenopausal period, onset of menopause
was associated with increased risk of current asthma (OR, 1.25;
95% CI, 1.04-1.51) (Fig E3), and with an increased risk of new-
onset asthma in one study,E68 but a decreased risk in another.E69
Each type of menopause (natural vs surgical) was associated
with an increased risk of current asthma in one study,E36 but a
decreased risk of new-onset asthma in another study.E69 One
study found a significantly higher exacerbation rate in women
who developed asthma around the time of their menopause than
in women with preexisting asthma.E15 Another found that exacer-
bations were reported most frequently by women in early post-
menopause, followed by those in late postmenopause or the
menopausal transition, and those who were premenopausal; how-
ever, no significance tests were performed.E68 This study found
the same pattern of reporting for current asthma medication
use.E68 Onset of menopause was associated with increased risk
of current wheeze (OR, 1.16; 95% CI, 1.05-1.30), but not current
allergic rhinitis (OR, 0.94; 95% CI, 0.81-1.10) (Fig E3).
Associations between exogenous sex hormones
and risk of asthma and allergy
Results of studies on use of hormonal contraceptives were
mixed, with both increased and decreased risks reported across
studies (data available on request). Compared with never use,
neither current (OR, 1.16; 95% CI, 0.73-1.85) nor past combined
oral contraceptive pill (OCP) use (OR, 0.68; 95% CI, 0.24-1.94)
was associated with current asthma (Fig E3). Although previous
use of oral contraceptives was associated with an increased risk
of new-onset asthma in one study,E69 a decreased risk after use
of hormonal contraceptives was reported in another (hormonal
compositions were not specified).E71 In one study, use of any hor-
monal contraceptive was associated with increased risk of having
3 ormore asthma orwheeze care episodes in the past 12months.E5
In another, women using the combined OCP were less likely to
report using inhaled corticosteroid medication than women not
usingOCP.E61 One study investigated the role of types of hormon-
al contraceptives (combined OCP and progesterone-only prepara-
tions compared with nonuse), but found no association with the
risk of either current asthma or current asthma or wheeze care ep-
isodes.E5 The duration of use of hormonal contraceptives was
generally not associated with any outcome (data available on
request). Current combined OCP use was not associated with cur-
rent wheeze (OR, 0.96; 95% CI, 0.72-1.28) (Fig E3). Two exper-
imental studies (CCTs) compared OCP to no OCP: mean FEV1/
forced vital capacity % was significantly greater in the interven-
tion group than in the control group in one studyE46; the opposite
occurred in the other.E58
Compared with never use, ever use of any HRT (HR, 1.37; 95%
CI, 1.22-1.54), past use of any HRT (HR, 1.41; 95% CI, 1.22-
1.63), current use of any HRT (HR, 1.48; 95% CI, 1.22-1.78), and
current use of estrogen-only HRT (HR, 1.85; 95% CI, 1.50-2.28)
were associated with increased risk of new-onset asthma (Fig 2).
Current use was also associated with increased risk of current
asthma (OR, 1.42; 95% CI, 1.18-1.70) (Fig 2). One study found
an increased risk of first-ever asthma hospitalization with ever,
previous, and current use of HRT (but not when HRT had been
tried for<6months); use of estrogen-only, sequential, and contin-
uous HRT; as well as increased risk for every 5 years of HRT
use.E18 Another found a lower exacerbation rate in women using
combined HRT than in those not using HRT.E11,E12 Two studies
found no association between asthma medication use and HRT
use.E39,E47 Current use of HRT was associated with increased
risk of current wheeze (OR, 1.40; 95%CI, 1.22-1.61), but not cur-
rent allergic rhinitis (OR, 1.27; 95% CI, 0.97-1.68) (Fig 2). Strat-
ified analyses indicated increased risk of asthma onset in both
nonoverweight/nonobese and overweight/obese women using
HRT; however, HRT use was associated with current asthma, cur-
rent wheeze, and current allergic rhinitis in nonoverweight/non-
obese but not overweight/obese women (Fig E4). Stratified
analyses also indicated increased risk of asthma onset and current
asthma in nonsmoking, but not ever-smoking women taking HRT
(Fig E4). In the 4 experimental studies (1 CCT and 3 RCTs) that
investigated the effects of different HRT regimens (comparing
combined and estrogen-only regimens to placebo or no HRT)
on lung performance, results were mixed.E10,E20,E55,E65
Risk of bias within studies
Overall, 41 of 51 observational studies were graded moderate
risk of bias, whereas the rest were graded high risk of bias. All 6
experimental studies had high risk of bias. Overall and domain-
specific risk-of-bias ratings for each study are available on
request. Funnel plots indicated more symmetry for studies on
menstruation and HRT than for studies on menarche, menopause,
and hormonal contraceptives (available on request). The associ-
ated P values for Egger test were as follows: menstruation
P 5 .295; HRT P 5 .999; menarche P 5 .108; menopause
P 5 .831; hormonal contraceptives P 5 .057.
APPENDIX E1. MEDLINE SEARCH STRATEGY—
NOVEMBER 11, 2015
1 exp Puberty/or puberty.mp.
2 exp Menarche/or menarche.mp.
3 exp Menstruation/or exp Menstruation Disturbances/or
menstruation.mp.
4 exp Menopause, Premature/or exp Postmenopause/or
menopause.mp.
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5 sex hormones.mp. or exp Gonadal Steroid Hormones/or exp
Estrogens/or estrogens.mp. or exp Progesterone/or progestero-
ne.mp. or Testosterone Congeners/or testosterone.mp. or exp
Testosterone/or Testosterone Propionate/
6 exp Contraceptive Agents/or contraceptives.mp. or exp Con-
traceptives, Oral/or oral contraceptives.mp. or exp Contracep-
tives, Oral, Combined/or combined oral contraceptives.mp. or
exp Medroxyprogesterone Acetate/or exp Contraceptive
Agents, Female/or exp Contraceptives, Oral, Hormonal/or
exp Contraception/or hormonal contraceptives.mp. or exp
Ethinyl Estradiol/
7 exp Hormone Replacement Therapy/or exp Estradiol/or hor-
mone replacement therapy.mp.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp Asthma/or asthma.mp.
10 wheeze.mp.
11 exp Dermatitis, Atopic/or atopic eczema.mp.
12 exp Hypersensitivity, Immediate/or exp Hypersensitivity/or
atopy.mp. or allergy.mp. or atopic sensitisation.mp. or
allergic sensitisation.mp.
13 exp Rhinitis, Allergic, Seasonal/or exp Rhinitis, Allergic,
Perennial/or exp Allergens/or allergic rhinitis.mp.
14 exp Conjunctivitis, Allergic/or Rhinoconjunctivitis.mp.
15 exp Conjunctivitis, Allergic/or Rhinoconjunctivitis.mp.
16 exp Urticaria/or urticarial.mp.
17 exp Angioedema/or angioedema.mp.
18 exp Food Hypersensitivity/or food allergy.mp.
19 exp Anaphylaxis/or anaphylaxis.mp.
20 lung function.mp.
21 airway function.mp. or exp Bronchial Hyperreactivity/
22 exp Forced Expiratory Volume/or forced expiratory volume
in 1 second.mp.
23 exp Peak Expiratory Flow Rate/or peak expiratory flow.mp.
24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or
20 or 21 or 22 or 23
25 8 and 24
26 limit 25 to female
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FIG E1. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow diagram
summarizing the identification, screening, eligibility, and inclusion of studies that investigated associations
between endogenous and exogenous sex steroid hormonal factors and asthma and allergy in females. For
Google Scholar, the first 400 hits were selected for screening.
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FIG E2. A, Meta-analyses of studies that investigated associations between irregular menstruation and
asthma and allergy in females. B,Meta-analyses of studies that investigated associations between irregular
menstruation and asthma in females, stratified by atopy. N.Europe, Northern Europe. All effect estimates
are adjusted. The comparator group in each analysis is regular menstruation.
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FIG E3. Meta-analyses of studies that investigated associations between onset of menopause and asthma
and allergy in females (A) and between OCP use and asthma and allergy in females (B).N.Europe, Northern
Europe. All effect estimates are adjusted. The comparator group is premenopause (A)/never use (B).
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FIG E4. Meta-analyses of studies that investigated associations between the use of HRT and asthma and
allergy in females, stratified by overweight/obesity (A) and smoking status (B). N.Europe, Northern Europe.
All effect estimates are adjusted. The comparator group in each analysis is never use.
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